CDK2 and cholangiocarcinoma: Molecular docking studies have demonstrated that derivatives of zerumbone with the presence of amine, epoxyamine, hydroxylamine, and nitrile groups can exhibit potent anti-cancer activities against CCA cells by interacting with the molecular target EGFR, but not CDK-2, CDK-5, and GSK-3.